June 6, 2023: The U.S. Preventive Services Task force has changed its recommendations for mammography to start at age 40 instead of 50. However, they still recommend mammograms every 2 years instead of every year. We point out that there are racial differences in cancer risk and that mammography guidelines should reflect those racial differences. One size does not fit all.
Read More »Medical Care for Adults
The National Center for Health Research reviews important new research as soon as it is published. We cut through the hype regarding various medical treatments to let you know what is proven and what is unknown about the risks and benefits of various treatment options. We do not accept funding from the companies that make medical products, so you can trust that our information is based on science, and not biased by financial ties to the treatments we’re evaluating.
To find the information you need, please use our search box to search for exactly what you are looking for or browse through our various topics on the right. →
Some of these articles were written this year and others were not, however, if they are on our website it means the information is up-to-date. We always scrutinize new research and call the researchers to learn even more. Then we translate it into plain language that everyone can understand.
If you’re looking for more detailed information about cancer, please go to our Cancer Prevention and Treatment website.
If you don’t see what you are looking for on any health topic, please contact us and we will try to get the information you need within a few days.
Cambridge biotech Sarepta wins fast-track approval for the first muscular dystrophy gene therapy
The Boston Globe, June 22, 2023: FDA has approved Sarepta’s gene therapy for Duchenne muscular dystrophy, which will cost $3.2 million per patient. FDA’s Peter Marks praises the drug as if he is a Sarepta salesman, and NCHR explains why this political compromise is harmful to patients.
Read More »Pricey Alzheimer’s Drug Coverage Hinges on FDA Decision
Bloomberg News, June 15, 2023: If Leqembi is approved, it will take time for doctors to arrange for patients to be tested for mild cognitive impairment and amyloid plaques on the brain, get the Leqembi infusions, and sign up patients for a registry. NCHR praises the CMS Registry as a good choice, but industry-funded groups complain.
Read More »US FDA adcom supports Leqembi for full approval
BioWorld, June 9, 2023: BioWorld news explains that FDA Advisory Committee supports Leqembi for Mild Cognitive Impairment (MCI) caused by Alzheimer’s and quotes our statement that MCI can go away without drugs, which means that Leqembi’s risks of brain swelling and bleeding will often greatly outweigh the potential benefits.
Read More »NCHR Comments on the Filing of Color Additive Petition to FDA from the Center for Science in the Public Interest
May 18, 2023: We support the request that the FDA ban the use of FD&C Red No. 3 in foods, drugs, and dietary supplements. We find it unacceptable that the FDA has known for more than 30 years that Red 3 can cause cancer and yet still allows the dye to be used in foods, drugs, and supplements.
Read More »